Overview
Nicholas Lafont provided legal advice to investors of Alize Pharma SAS, an Alize Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases, in its new financing round of EUR 5 million to fund the completion of clinical trials.